Epigenetic Switch–Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Tumor progression upon treatment arises from preexisting resistant cancer cells and/or adaptation of persister cancer cells committing to an expansion phase. Here, we show that evasion from viral mimicry response allows the growth of taxane-resistant triple-negative breast cancer (TNBC). This is enabled by an epigenetic state adapted to taxane-induced metabolic stress, where DNA hypomethylation over loci enriched in transposable elements (TE) is compensated by large chromatin domains of H3K27me3 to warrant TE repression. This epigenetic state creates a vulnerability to epigenetic therapy against EZH2, the H3K27me3 methyltransferase, which alleviates TE repression in taxane-resistant TNBC, leading to double-stranded RNA production and growth inhibition through viral mimicry response. Collectively, our results illustrate how epigenetic states over TEs promote cancer progression under treatment and can inform about vulnerabilities to epigenetic therapy. Significance: Drug-resistant cancer cells represent a major barrier to remission for patients with cancer. Here we show that drug-induced metabolic perturbation and epigenetic states enable evasion from the viral mimicry response induced by chemotherapy in TNBC. These epigenetic states define a vulnerability to epigenetic therapy using EZH2 inhibitors in taxane-resistant TNBC. See related commentary by Janin and Esteller, p. 1258. This article is highlighted in the In This Issue feature, p. 1241
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.011 · Cited by 2,022
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D. P., Adam, J., Vitale, I., Goubar, A., Baracco, E. E., Remédios, C., et al. (2014) · Nature Medicine · doi:10.1038/nm.3708 · Cited by 1,042
The role of methionine on metabolism, oxidative stress, and diseases
Martínez, Y., Li, X., Liu, G., Bin, P., Yan, W., Más, D., Valdivié, M., Hu, C.-A. A., Ren, W., & Yin, Y. (2017) · Amino Acids · doi:10.1007/s00726-017-2494-2 · Cited by 583 · cited 1×
“Accordingly, increased dependency on exogenous l-methionine in taxane-resistant TNBC cells may provide substrates to sustain glutathione-mediated antioxidant capacity despite cytotoxic drug exposure (19, 29).”
BackgroundHon, G. C., Hawkins, R. D., Caballero, O. L., Lo, C., Lister, R., Pelizzola, M., Valsesia, A., Ye, Z., Kuan, S., Edsall, L. E., et al. (2012) · Genome Research · doi:10.1101/gr.125872.111 · Cited by 583 · cited 1×
“Our observations also align with reports of H3K27me3 and other repressive histone modifications compensating for DNA hypomethylation to ensure genome stability in mouse embryonic stem cells (36) and to maintain transcriptional repression across various cancer types (37).”
ResultDiverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581 · cited 2×
“Diverse metabolic adaptations support the development of drug-resistant cancer cells under the stressful environment that stems from therapy (1, 26).”
BackgroundHigh-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Grosselin, K., Durand, A., Marsolier, J., Poitou, A., Marangoni, E., Nemati, F., Dahmani, A., Lameiras, S., Reyal, F., Frenoy, O., et al. (2019) · Nature Genetics · doi:10.1038/s41588-019-0424-9 · Cited by 466 · cited 1×
“Metabolic perturbations can thus favor transitions in epigenetic states, a feature of cancer initiation (6) and progression (7).”
BackgroundLKB1 loss links serine metabolism to DNA methylation and tumorigenesis
Kottakis, F., Nicolay, B. N., Roumane, A., Karnik, R., Gu, H., Nagle, J. M., Boukhali, M., Hayward, M. C., Li, Y. Y., Chen, T., et al. (2016) · Nature · doi:10.1038/nature20132 · Cited by 348 · cited 3×
“This parallels changes in LINE1 DNA methylation observed upon alterations in one-carbon metabolism induced either genetically or through the diet in pancreatic and breast cancer models (4, 33, 34).”
BackgroundWalter, M., Teissandier, A., Pérez-Palacios, R., & Bourc'his, D. (2016) · eLife · doi:10.7554/elife.11418 · Cited by 303 · cited 1×
“Our observations also align with reports of H3K27me3 and other repressive histone modifications compensating for DNA hypomethylation to ensure genome stability in mouse embryonic stem cells (36) and to maintain transcriptional repression across various cancer types (37).”
ResultGuler, G. D., Tindell, C. A., Pitti, R., Wilson, C., Nichols, K., KaiWai Cheung, T., Kim, H.-J., Wongchenko, M., Yan, Y., Haley, B., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.002 · Cited by 277 · cited 4×
“This is exemplified by changes in the distribution of H3 lysine 4 dimethylation (H3K4me2) and lysine 36 trimethylation (H3K36me3) in endocrine therapy–resistant luminal breast cancer cells (11) and by the formation of repressed chromatin states characterized by increased methylation of H3 lysines 9 and 27 (H3K9 and H3…”
BackgroundInfluentialThe Influence of Metabolism on Drug Response in Cancer
Zaal, E. A., & Berkers, C. R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00500 · Cited by 272 · cited 1×
“Diverse metabolic adaptations support the development of drug-resistant cancer cells under the stressful environment that stems from therapy (1, 26).”
BackgroundInteractions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82 · cited 1×
“Although the sensitivity of different methyltransferases to changes in SAM availability depends on cell type and developmental stage (38), the fact that global decreases in DNA methylation observed in taxane-resistant TNBC cells are not paralleled with a global decrease in H3K27me3 levels agrees with the higher Michae…”
BackgroundSelf-citation
Cited by
Epigenetic mechanisms in breast cancer therapy and resistance
Garcia-Martinez, L., Zhang, Y., Nakata, Y., Chan, H. L., & Morey, L. (2021) · Nature Communications · doi:10.1038/s41467-021-22024-3 · Cited by 458
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer
Wu, Q., ba-alawi, W., Deblois, G., Cruickshank, J., Duan, S., Lima-Fernandes, E., Haight, J., Tonekaboni, S. A. M., Fortier, A.-M., Kuasne, H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18020-8 · Cited by 305
Self-citationSo, J. Y., Ohm, J., Lipkowitz, S., & Yang, L. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108253 · Cited by 256
The interplay between DNA and histone methylation: molecular mechanisms and disease implications
Li, Y., Chen, X., & Lu, C. (2021) · The EMBO Reports · doi:10.15252/embr.202051803 · Cited by 223
Metadata
- Authors
- Deblois, G., Tonekaboni, S. A. M., Grillo, G., Martinez, C., Kao, Y. I., Tai, F., Ettayebi, I., Fortier, A.-M., Savage, P., Fedor, A. N., Liu, X., Guilhamon, P., Lima-Fernandes, E., Murison, A., Kuasne, H., Ba-alawi, W., Cescon, D. W., Arrowsmith, C. H., De Carvalho, D. D., Haibe-Kains, B., Locasale, J. W., Park, M., & Lupien, M.
- Venue
- Cancer Discovery
- Published
- 2020-09-01
- Volume
- 10
- Issue
- 9
- Pages
- 1312-1329
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W3035191018
- Cited by
- 147
- References
- 13
- FWCI
- 5.39
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.